408 related articles for article (PubMed ID: 16080523)
1. Serum levels of interleukin-6 in patients with primary head and neck squamous cell carcinoma.
Riedel F; Zaiss I; Herzog D; Götte K; Naim R; Hörmann K
Anticancer Res; 2005; 25(4):2761-5. PubMed ID: 16080523
[TBL] [Abstract][Full Text] [Related]
2. Serum levels of matrix metalloproteinase-2 and -9 in patients with head and neck squamous cell carcinoma.
Riedel F; Götte K; Schwalb J; Hörmann K
Anticancer Res; 2000; 20(5A):3045-9. PubMed ID: 11062721
[TBL] [Abstract][Full Text] [Related]
3. Investigation of interleukin 10, 12 and 18 levels in patients with head and neck cancer.
Jebreel A; Mistry D; Loke D; Dunn G; Hough V; Oliver K; Stafford N; Greenman J
J Laryngol Otol; 2007 Mar; 121(3):246-52. PubMed ID: 17040593
[TBL] [Abstract][Full Text] [Related]
4. Elevated serum levels of M30 and M65 in patients with locally advanced head and neck tumors.
Ozturk B; Coskun U; Sancak B; Yaman E; Buyukberber S; Benekli M
Int Immunopharmacol; 2009 May; 9(5):645-8. PubMed ID: 19249390
[TBL] [Abstract][Full Text] [Related]
5. Expression of IL-18 in patients with head and neck squamous cell carcinoma.
Riedel F; Adam S; Feick P; Haas S; Götte K; Hörmann K;
Int J Mol Med; 2004 Feb; 13(2):267-72. PubMed ID: 14719133
[TBL] [Abstract][Full Text] [Related]
6. Expression of proinflammatory and proangiogenic cytokines in patients with head and neck cancer.
Chen Z; Malhotra PS; Thomas GR; Ondrey FG; Duffey DC; Smith CW; Enamorado I; Yeh NT; Kroog GS; Rudy S; McCullagh L; Mousa S; Quezado M; Herscher LL; Van Waes C
Clin Cancer Res; 1999 Jun; 5(6):1369-79. PubMed ID: 10389921
[TBL] [Abstract][Full Text] [Related]
7. The significance of Tenascin-C serum level as tumor marker in squamous cell carcinoma of the head and neck.
Pauli C; Stieber P; Schmitt UM; Andratschke M; Hoffmann K; Wollenberg B
Anticancer Res; 2002; 22(5):3093-7. PubMed ID: 12530049
[TBL] [Abstract][Full Text] [Related]
8. Interleukin-6 predicts recurrence and survival among head and neck cancer patients.
Duffy SA; Taylor JM; Terrell JE; Islam M; Li Y; Fowler KE; Wolf GT; Teknos TN
Cancer; 2008 Aug; 113(4):750-7. PubMed ID: 18536030
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of soluble CD44v6 as a potential serum marker for head and neck squamous cell carcinoma.
Van Hal NL; Van Dongen GA; Ten Brink CB; Heider KH; Rech-Weichselbraun I; Snow GB; Brakenhoff RH
Clin Cancer Res; 1999 Nov; 5(11):3534-41. PubMed ID: 10589769
[TBL] [Abstract][Full Text] [Related]
10. Serum hepatocyte growth factor as a marker of tumor activity in head and neck squamous cell carcinoma.
Kim CH; Lee JS; Kang SO; Bae JH; Hong SP; Kahng H
Oral Oncol; 2007 Nov; 43(10):1021-5. PubMed ID: 17306605
[TBL] [Abstract][Full Text] [Related]
11. Serum biomarkers in head and neck squamous cell cancer.
Kaskas NM; Moore-Medlin T; McClure GB; Ekshyyan O; Vanchiere JA; Nathan CA
JAMA Otolaryngol Head Neck Surg; 2014 Jan; 140(1):5-11. PubMed ID: 24232368
[TBL] [Abstract][Full Text] [Related]
12. Defining cancer cachexia in head and neck squamous cell carcinoma.
Richey LM; George JR; Couch ME; Kanapkey BK; Yin X; Cannon T; Stewart PW; Weissler MC; Shores CG
Clin Cancer Res; 2007 Nov; 13(22 Pt 1):6561-7. PubMed ID: 18006755
[TBL] [Abstract][Full Text] [Related]
13. Soluble interleukin-2 receptor serum level as a predictor of locoregional control and survival for patients with head and neck carcinoma: results of a multivariate prospective study.
Tartour E; Deneux L; Mosseri V; Jaulerry C; Brunin F; Point D; Validire P; Dubray B; Fridman WH; Rodriguez J
Cancer; 1997 Apr; 79(7):1401-8. PubMed ID: 9083163
[TBL] [Abstract][Full Text] [Related]
14. Tissue inhibitor of matrix metalloproteinase-1 is prognostic in head and neck squamous cell carcinoma: comparison of the circulating and tissue immunoreactive protein.
Ruokolainen H; Pääkkö P; Turpeenniemi-Hujanen T
Clin Cancer Res; 2005 May; 11(9):3257-64. PubMed ID: 15867221
[TBL] [Abstract][Full Text] [Related]
15. DNA ploidy, proliferative capacity and intratumoral heterogeneity in primary and recurrent head and neck squamous cell carcinomas (HNSCC)--potential implications for clinical management and treatment decisions.
Hass HG; Schmidt A; Nehls O; Kaiser S
Oral Oncol; 2008 Jan; 44(1):78-85. PubMed ID: 17350326
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of soluble adhesion molecules CD44 (CD44st, CD44v5, CD44v6), ICAM-1, and VCAM-1 as tumor markers in head and neck cancer.
Kawano T; Yanoma S; Nakamura Y; Shiono O; Kokatu T; Kubota A; Furukawa M; Tsukuda M
Am J Otolaryngol; 2005; 26(5):308-13. PubMed ID: 16137528
[TBL] [Abstract][Full Text] [Related]
17. Serum concentrations of interleukin-8, vascular endothelial growth factor, and epidermal growth factor receptor in patients with squamous cell cancer of the head and neck.
Gokhale AS; Haddad RI; Cavacini LA; Wirth L; Weeks L; Hallar M; Faucher J; Posner MR
Oral Oncol; 2005 Jan; 41(1):70-6. PubMed ID: 15598588
[TBL] [Abstract][Full Text] [Related]
18. Serum nitric oxide levels in patients with head and neck squamous cell carcinoma.
Kizilay A; Kalcioğlu MT; Ozuğurlu F; Ozyurt H; Aladağ I; Ozturan O; Akyol O
Kulak Burun Bogaz Ihtis Derg; 2007; 17(3):148-51. PubMed ID: 17873505
[TBL] [Abstract][Full Text] [Related]
19. Relationship between serum levels of interleukin 6, various disease parameters and malnutrition in patients with esophageal squamous cell carcinoma.
Oka M; Yamamoto K; Takahashi M; Hakozaki M; Abe T; Iizuka N; Hazama S; Hirazawa K; Hayashi H; Tangoku A; Hirose K; Ishihara T; Suzuki T
Cancer Res; 1996 Jun; 56(12):2776-80. PubMed ID: 8665513
[TBL] [Abstract][Full Text] [Related]
20. Interleukin-13 receptor alpha2 chain in human head and neck cancer serves as a unique diagnostic marker.
Kawakami M; Kawakami K; Kasperbauer JL; Hinkley LL; Tsukuda M; Strome SE; Puri RK
Clin Cancer Res; 2003 Dec; 9(17):6381-8. PubMed ID: 14695138
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
